• Save
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my health system afford the cost?
Upcoming SlideShare
Loading in...5
×
 

Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my health system afford the cost?

on

  • 684 views

 

Statistics

Views

Total Views
684
Views on SlideShare
684
Embed Views
0

Actions

Likes
1
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my health system afford the cost? Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my health system afford the cost? Presentation Transcript

  • Personalized Medicine:
    Can a non-profit public organization
    afford it – and for what purpose ?
    Nicky Liebermann MD, Head – Community Medicine Division
    ShmuelKlang PHD, Head – Pharmacology and Pharmacy
    Clalit Health Services
  • February 13, 2006:
    ‘Clalit Health Services’ will fund the most advanced test for breast cancer patients that will determine if they require chemotherapy.
    The test, called 'Oncotype DX', allows identifying
    which patients will benefit from a chemotherapy
    treatment, and which patients can be spared this
    harsh treatment.
    A breakthrough and news for breast cancer patients:
  • Why ???
    The Israeli medical insurance system –
    National health law
    4 HMO’s as service and insurance givers
    COMPETITION !!!!
    Every quarter any ensuree can change HMO
    Fixed basal basket of services
    Fixed payments (by the state)
    So we can compete only on quality, service and innovation
  • Why
    In Israel, polls found that women lead the family and its decisions in the fields of education and health. So the woman will chose the physician, the HMO/health plan etc.
    OncotypeDX-Breast presented the opportunity to tell breast cancer patients, with a sound level of certainty that after the surgery they are probably healthy !!!
  • Last why
    A wide psychological gap exists between the definition of a cancer patient, and a “cured” one. This impacts the health status of the whole family, it’s life style, it’s spirit.
    Clalit decided to invest the needed amount in order to offer it’s customers this product and by it to try and promote the general and personal health status of these families.
  • The process
    Oncologists cooperation – Imperative !!!!
    Accepted guidelines/protocol
    Medical and economical survey and sharing of the DATA with the clinicians
    The decision was to introduce the new technology for Clalit’s ensurees – accompanied by a common research with the company and the oncologists
  • Method
    The medical division developed assigned form for OncotypeDX Breast approval.
    The form contains the following information:
    Tumor size and biological markers
    The treatment the patient would have received without OnctoypeDX Breast assay
    The treatment the patient would receive for each Recurrence Score range – INTENTION TO TREAT
    Finally, based on Clalit database the patients’ actual treatment was reviewed.
  • Analysis
    Comparing the proposed treatment the patient would have received without OncotypeDX Breast with the actual, post OncotypeDX treatment (Intention to treat vs final decision)
    Comparison with the pre-written treatment according to the future RS range with the actual treatment
  • Clalit leads the OncotypeDX breast assays performed annually in Israel
  • Clalit leads the OncotypeDX breast assays performed annually in Israel for Node + breast cancer patients
  • First change in the protocol was to approve the test for node+ cases – long before it was accepted by others.
  • Treatment Recommendation before and after OncotypeDX Breast testing(N=313)
  • Chemotherapy by Risk Level
  • Average Added Cost (Saving) Per Patient
    Average added cost$1828
    Oncotype
    Recurrence costs
    Supportive care
    Chemotherapy
    Adverse events
  • Economical and Clinical Applications
    The use of OncotypeDX Breast assay changed the treatment recommendation in 40% of the cases
    84% Shifted from hormonal therapy+ chemo to hormonal therapy only.
    8% of high risk patients by RS shifted from hormonal therapy to hormonal +chemo.
    The assay cost was partially funded by saving the chemotherapy and side effects related treatment costs.
  • The quality-adjusted life year (QALY) is a measure of disease burden, including both the quality and the quantity of life lived.
    Shifting from combination Chemo+Hormonal therapy to Hormonal therapy only = side effect prevention and better health status.
    Preventing disease recurrence for some of the patients found to be high risk by the assay.
    QALYs Gain
  • Cost-effectiveness ratio
    The QALY is based on the number of years of life that would be added by the intervention. Each year in perfect health is assigned the value of 1.0 down to a value of 0.0 for death.
    Cost with Oncotype DX – Cost without Oncotype DX
    QALYs with Oncotype DX – QALYs without Oncotype DX
    $1,828
    = $10,770 per QALY gained
    0.170 QALYs
  • NEJM: 2005: 353(14):1516-1521
  • Conclusion – Oncotype DX resulted in net QALY gain and increased overall costs, with an incremental cost effectiveness ratio of 10,770 $ per QALY gained.
    Oncotype DX represents an effective and affordable approach to favorably affect the lives of women with ESBC.
  • OncotypeDX breast N+ poster at ASCO 2010
  • OncotypeDX was used primarily in patients with micro-metastases, and 1 positive node (84% of patient population).
    Treatment decisions in these node-positive breast cancer patients was influenced primarily by the RS results and then by the nodal status.
    Patients with Nmic and RS<31 received less chemotherapy than patients with N1-3 and RS<31.
    All patients with RS>31 received adjuvant chemotherapy.
    OncotypeDX breast N+ poster at ASCO 2010- main points
  • Ongoing studies of Clalit with OncotypeDX breast
    Comparing treatment decision in N+ cases with RS data vs. matching control cases not analyzed for RS.
    Comparing the real recurrences vs. RS in the Clalit database of over 3,000 cases.
    ER, PR, HER2 status by IHC compared with that in RT-PCR by OncotypeDX.
    Evaluation of the RS predictive value by clinico-pathological factors.
  • Who is in the high risk group?
    Stage II colorectal patients
    Low Risk patients
    High Risk patients
    30-50% ?
    50-70% ?
    1. Perforation
    94-95% 5y survival
    2. Lympho-vascular involvement
    3.Perineural invasion
    4. Preoperative CEA
    5. Obstruction
    6. < 10-12 lymph nodes examined
    7. Poor Tumor differentiation
    8. T4
    9. Tumor budding
    DFS =4%, OS 1-2% (NS)
  • Profiles & Biomarkers Used in Clalit
    OncotypeDX Breast: Early breast cancer
    OncotypeDX Colon: Stage II colon cancer
    miRview mets: Carcinoma unknown primary
    K-RAS: Metastatic colon cancer
    EGFR: Non small cell lung cancer
  • Conclusions 1
    Although “money makes the world go around”, there are other values to gain by implementing this new technology – better medical quality & accuracy, better quality of life for the patients & families, and, may be, with the improvement in the technology of “directing therapy” – targeted medicine, that will be even cost efficient because inefficient treatments will be avoided.
  • Conclusions 2
    Implementation of a new technology should be supported by –
    Agreement/acceptance of the profession
    Defined/accepted protocol of use
    Registered follow up of cases
    Sharing the results with the clinicians
  • Thank you